Home ETF List About

ETF Holdings Breakdown of ARQT

Stock NameArcutis Biotherapeutics Inc
TickerARQT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS03969K1088

ARQT institutional holdings

The adjusted close for ARQT on 2025-11-12 was 23.45

The following institutional investment holdings of ARQT have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-12 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 87,717USD 2,056,964 -2.5% 23.45  
2025-11-12 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 54,977 -0.3%USD 1,289,211 -2.8% 23.45  
2025-11-12 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 77,145USD 1,809,050 23.45  
2025-11-12 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 77,145 0.3%USD 1,809,050 -2.2% 23.45  
2025-11-12 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 2,324USD 54,498 -2.5% 23.45  
Total =299,308 USD 7,018,773
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with ARQT

Zurcher Kantonalbank Zurich Cantonalbank Raises Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 3.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 29,697 shares of the company’s stock after purchasing an additional 917 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Arcutis Biotherapeutics were worth $464,000 at the […] - 2025-08-08 04:56:49
Arcutis Biotherapeutics (NASDAQ:ARQT) Coverage Initiated at The Goldman Sachs Group
The Goldman Sachs Group began coverage on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a research report released on Friday, MarketBeat.com reports. The brokerage issued a neutral rating and a $18.00 price target on the stock. A number of other brokerages have also commented on ARQT. Needham & Company LLC reiterated a “buy” […] - 2025-07-28 02:05:01
Patrick Burnett Sells 23,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of the company’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $15.05, for a total value of $346,150.00. Following the sale, the insider owned 115,468 shares of the company’s stock, valued at […] - 2025-07-16 05:29:11
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have received an average recommendation of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price […] - 2025-07-10 05:48:58
SG Americas Securities LLC Has $509,000 Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
SG Americas Securities LLC lowered its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 32.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,566 shares of the company’s stock after selling 15,521 shares during the period. SG Americas Securities […] - 2025-06-23 04:29:10
Wealth Enhancement Advisory Services LLC Purchases Shares of 20,912 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 20,912 shares of the company’s stock, valued at approximately $291,000. Other hedge funds and other institutional investors have also bought and sold shares of the […] - 2025-06-16 04:08:49
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 280,100 shares of the company’s stock […] - 2025-06-05 05:16:57
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Deutsche Bank AG
Deutsche Bank AG lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 51.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 387,536 shares of the company’s stock after selling 412,491 shares during the quarter. Deutsche Bank AG’s holdings […] - 2025-05-19 05:07:00
Northern Trust Corp Purchases 54,541 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Northern Trust Corp increased its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 5.8% during the fourth quarter, HoldingsChannel reports. The fund owned 991,056 shares of the company’s stock after buying an additional 54,541 shares during the quarter. Northern Trust Corp’s holdings in Arcutis Biotherapeutics were worth $13,805,000 at the end […] - 2025-05-16 04:22:56
Schonfeld Strategic Advisors LLC Sells 7,349 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Schonfeld Strategic Advisors LLC lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 24.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,000 shares of the company’s stock after selling 7,349 shares during the quarter. Schonfeld Strategic Advisors […] - 2025-05-13 06:15:01
Price T Rowe Associates Inc. MD Reduces Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Price T Rowe Associates Inc. MD decreased its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 29.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,349 shares of the company’s stock after selling 17,799 shares during the […] - 2025-05-13 04:32:49
Voya Investment Management LLC Sells 2,472 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Voya Investment Management LLC trimmed its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 7.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,136 shares of the company’s stock after selling 2,472 shares during the period. Voya Investment […] - 2025-05-11 05:44:48
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Boosted by Tower Research Capital LLC TRC
Tower Research Capital LLC TRC grew its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 62.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,231 shares of the company’s stock after buying an additional 5,488 shares during the quarter. […] - 2025-05-06 05:09:04
Wells Fargo & Company MN Has $731,000 Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Wells Fargo & Company MN increased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 46.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 52,455 shares of the company’s stock after purchasing an additional 16,682 shares during the quarter. Wells Fargo & Company MN’s holdings in Arcutis Biotherapeutics were […] - 2025-05-02 04:18:56
Geode Capital Management LLC Increases Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Geode Capital Management LLC boosted its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,472,730 shares of the company’s stock after buying an additional 2,592 shares during the quarter. Geode Capital Management LLC’s holdings in Arcutis Biotherapeutics were worth $34,453,000 as of […] - 2025-04-17 05:18:49
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Wellington Management Group LLP
Wellington Management Group LLP lowered its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 7.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 49,267 shares of the company’s stock after selling 3,882 shares during the quarter. Wellington Management Group LLP’s holdings in Arcutis Biotherapeutics […] - 2025-04-15 04:46:50
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by CIBC Private Wealth Group LLC
CIBC Private Wealth Group LLC reduced its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 18.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 7,782 shares of the company’s stock after selling 1,776 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Arcutis […] - 2025-04-08 06:03:20
Teacher Retirement System of Texas Boosts Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Teacher Retirement System of Texas grew its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 19.5% during the 4th quarter, HoldingsChannel reports. The fund owned 31,216 shares of the company’s stock after purchasing an additional 5,087 shares during the period. Teacher Retirement System of Texas’ holdings in Arcutis Biotherapeutics were worth $435,000 at […] - 2025-04-01 04:40:45
Intech Investment Management LLC Buys 5,168 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Intech Investment Management LLC boosted its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 13.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 42,258 shares of the company’s stock after acquiring an additional 5,168 shares during the period. Intech Investment Management LLC’s holdings in Arcutis Biotherapeutics were worth $589,000 […] - 2025-03-25 06:29:08
AlphaQuest LLC Decreases Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
AlphaQuest LLC lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 83.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 7,142 shares of the company’s stock after selling 35,696 shares during the quarter. AlphaQuest LLC’s holdings in Arcutis Biotherapeutics were worth $99,000 as of its most recent filing […] - 2025-03-19 06:10:46
Bank of New York Mellon Corp Cuts Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Bank of New York Mellon Corp decreased its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 305,007 shares of the company’s stock after selling 6,052 shares during the period. Bank […] - 2025-03-19 05:08:45
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says
Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price target lifted by Jefferies Financial Group from $16.00 to $19.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock. Other research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating […] - 2025-03-12 04:56:51
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Mizuho Analyst Says
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) had its target price lifted by stock analysts at Mizuho from $20.00 to $21.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s target price suggests a potential upside of 64.06% from the stock’s previous close. A number of […] - 2025-02-28 04:52:44

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.